Piramal Pharma Receives GST Demand and Penalty Order Totaling ₹8.12 Crore
Piramal Pharma Ltd · Others (Uncategorized) · 29 Sept 2026, 4:29 pm
Piramal Pharma Receives GST Demand and Penalty Order Totaling ₹8.12 Crore Piramal Pharma received an Order-in-Original from CGST Mumbai East confirming an Input Tax Credit demand of Rs. 4.06 cr along with applicable interest and an equivalent penalty of Rs. 4.06 cr for FY'21 to FY'23. The tax dispute pertains to post-demerger transitional ITC, ISD registrations, and cross-charged expenses from Piramal Enterprises. The company intends to appeal the order before appellate authorities within prescribed timelines and expects no material impact on its financials or operations.
Original exchange filing (PDF)
More announcements from Piramal Pharma Ltd
- Please find enclosed intimation of the exercise of call option to acquire the balance 26% equity stake in Yapan Bio Private Limited. · 18 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund · 31 Oct 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015 · 30 Oct 2026
- Please find enclosed details of Earning call Transcript held on 28th October 2026. · 30 Oct 2026
- Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026. · 28 Oct 2026
- Please find enclosed Investor presentation for quarter ended 30 September, 2026 · 28 Oct 2026
- Please find enclosed Press release for quarter ended 30 September, 2026 · 28 Oct 2026
- Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 28 Oct 2026
